Cannabis-related schizophrenia is on the rise in Ontario, Canada, according to a new study published in JAMA Network Open. Researchers have identified a significant increase in schizophrenia cases connected to cannabis use disorder (CUD), with proportions jumping from 3.7% before marijuana legalisation to 10.3% afterward.

Canada’s relaxed marijuana regulations have raised concerns about its mental health impacts. The study highlights that marijuana potency has doubled in recent years, with over 70% of dried cannabis sold in Ontario now containing THC levels higher than 20%. This increase in strength correlates with growing emergency department visits for cannabis-induced psychosis and CUD.

From 2006 to 2022, the number of Ontario adults engaging in high-risk cannabis use behaviours rose by 145.5%. Issues such as dependency and social problems tied to marijuana-linked schizophrenia grew by an alarming 223.3%, underscoring the severe threats posed by excessive cannabis use.

The study identified younger males as particularly vulnerable, linking 18.9% of schizophrenia cases in this group to CUD by its conclusion. Dr Daniel Myran, the lead author and an affiliate of the University of Ottawa, commented, “The tripling of schizophrenia cases associated with a cannabis use disorder over the past 17 years and rising cases of psychosis underscores the urgent need for targeted prevention strategies, particularly for younger populations who appear to be at the greatest risk.”

With cannabis-related schizophrenia emerging as a significant concern, researchers are urging for targeted prevention efforts to protect at-risk groups, especially younger individuals.

Source: The Drug Report